Literature DB >> 11733480

In vitro susceptibility of clinical isolates of Zygomycota to amphotericin B, flucytosine, itraconazole and voriconazole.

A Gómez-López1, M Cuenca-Estrella, A Monzón, J L Rodriguez-Tudela.   

Abstract

The in vitro susceptibility of 29 clinical isolates of fungi belonging to the division Zygomycota was reviewed. A broth microdilution test was performed by following the NCCLS reference method, with minor modifications. The species of Zygomycota tested were resistant in vitro to flucytosine, itraconazole and voriconazole. Amphotericin B showed the best activity against most of the strains evaluated.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11733480     DOI： 10.1093/jac/48.6.919

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


  12 in total

Review 1.  [Strategies for antifungal treatment failure in intensive care units].

Authors:  C Arens; M Bernhard; C Koch; A Heininger; D Störzinger; T Hoppe-Tichy; M Hecker; B Grabein; M A Weigand; C Lichtenstern
Journal:  Anaesthesist       Date:  2015-09       Impact factor: 1.041

2.  Diagnosis of invasive aspergillosis and mucormycosis in immunocompromised patients by seminested PCR assay of tissue samples.

Authors:  V Rickerts; G Just-Nübling; F Konrad; J Kern; E Lambrecht; A Böhme; V Jacobi; R Bialek
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-01       Impact factor: 3.267

3.  Disseminated infection due to Saksenaea vasiformis secondary to cutaneous mucormycosis.

Authors:  Cristina Gómez-Camarasa; María Dolores Rojo-Martín; Consuelo Miranda-Casas; Ana Alastruey-Izquierdo; Luis Aliaga-Martínez; José Miguel Labrador-Molina; José María Navarro-Marí
Journal:  Mycopathologia       Date:  2013-11-01       Impact factor: 2.574

Review 4.  Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species.

Authors:  Marisa Z R Gomes; Russell E Lewis; Dimitrios P Kontoyiannis
Journal:  Clin Microbiol Rev       Date:  2011-04       Impact factor: 26.132

Review 5.  A rare presentation of zygomycosis (mucormycosis) and review of the literature.

Authors:  M Karanth; P Taniere; J Barraclough; J A Murray
Journal:  J Clin Pathol       Date:  2005-08       Impact factor: 3.411

Review 6.  Unpredictable susceptibility of emerging clinical moulds to tri-azoles: review of the literature and upcoming challenges for mould identification.

Authors:  R Araujo; M Oliveira; A Amorim; B Sampaio-Maia
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-04-18       Impact factor: 3.267

7.  Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.

Authors:  Ana Alastruey-Izquierdo; Maria Victoria Castelli; Isabel Cuesta; Araceli Monzon; Manuel Cuenca-Estrella; Juan Luis Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2009-01-26       Impact factor: 5.191

8.  Zygomycosis: an emerging fungal infection with new options for management.

Authors:  Carol A Kauffman; Anurag N Malani
Journal:  Curr Infect Dis Rep       Date:  2007-11       Impact factor: 3.725

Review 9.  Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.

Authors:  Marit D Moen; Katherine A Lyseng-Williamson; Lesley J Scott
Journal:  Drugs       Date:  2009       Impact factor: 9.546

10.  In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model.

Authors:  Qiu N Sun; Laura K Najvar; Rosie Bocanegra; David Loebenberg; John R Graybill
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.